This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q65389751
rdf:type
wikibase:Item
schema:description
klinisch onderzoek clinical trial ensayu clínicu клінічне випробування
rdfs:label
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
skos:prefLabel
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
schema:name
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
p:P1476
wds:Q65389751-7CD6DE21-99D4-4EC2-A642-9D3194037094
wdt:P1476
A Phase II Trial of E7389 (Halichondrin B Analog), in Patients With Metastatic Hormone Refractory Prostate Cancer
p:P582
wds:Q65389751-2E44813B-C536-4044-A1EB-A8C133928B58
wdt:P582
2009-06-01T00:00:00Z
p:P31
wds:Q65389751-32795E1C-23C2-40B8-B0E4-80A6BF1AD710
wdt:P31
wd:Q30612
p:P580
wds:Q65389751-BC59BAAD-F16A-443D-A7B5-3261D4442F83
wdt:P580
2006-11-01T00:00:00Z
p:P17
wds:Q65389751-29FC0C1C-3141-4546-A151-AF567F8376AD
wdt:P17
wd:Q30
p:P6153
wds:Q65389751-F9B5C0E2-1233-4208-BF94-1FFC699EC25F wds:Q65389751-F0DFAFFB-24DF-4036-B01F-44FBF55C86C7 wds:Q65389751-F4A2D884-5566-4C62-91B3-C35A60F84EA9 wds:Q65389751-A26A2363-6860-4DFD-B4AC-C9122DDC6A87 wds:Q65389751-AFB44401-6EDC-4082-A4F5-C90B3F2E9619 wds:Q65389751-DBAE4CD3-FDCD-41CC-B0BA-C5D6A1927976 wds:Q65389751-7744C677-562D-4407-91B7-E777189C5948 wds:Q65389751-93003CB2-72B9-46EE-8CA7-CCD2DF708D48 wds:Q65389751-4674F486-BCA7-4AFC-B4D6-9DF5FD727841 wds:Q65389751-5AB9FD61-D4DF-41FF-89B2-DFC15F96798F wds:Q65389751-40EBF5D8-E133-476C-B6DB-7A31CD36C0F0 wds:Q65389751-204434F9-1912-4C19-B369-B4AA2E4B6B23 wds:Q65389751-225DFA61-D013-4943-ABAC-6331F162453A
wdt:P6153
wd:Q4936104 wd:Q22033932 wd:Q5330089 wd:Q30280192 wd:Q6815474 wd:Q2302319 wd:Q1047060 wd:Q87932226 wd:Q5714832 wd:Q14716149 wd:Q1130172 wd:Q7338753 wd:Q49210
p:P4844
wds:Q65389751-3DF43530-3A79-4E99-BD6B-1222CC6072D2
wdt:P4844
wd:Q4993812
p:P2899
wds:Q65389751-9026ED7C-6F07-45E9-BEE1-D92657575743
wdt:P2899
18
p:P1050
wds:Q65389751-FC541514-E81A-4A3E-A80D-F1837C1C3E79
wdt:P1050
wd:Q356033
p:P1132
wds:Q65389751-E4A2BD32-EC2A-423D-BE34-52BDEF14E9D2
wdt:P1132
121
p:P8363
wds:Q65389751-F00DDE34-6291-4452-9456-7ACEB035DCE0
wdt:P8363
wd:Q78089383
p:P3098
wds:Q65389751-710948F1-6C83-4A7A-9A83-F0CDAF953ED1
wdt:P3098
NCT00337077
p:P6099
wds:Q65389751-5E534051-3F85-4048-96F6-435469C52013
wdt:P6099
wd:Q42824440